• Lancet · Jun 2002

    Randomized Controlled Trial Multicenter Study Clinical Trial

    Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.

    Magnesium sulphate halves the risk of eclampsia in pre-eclamptic pregnant women without significant adverse effect.

    pearl
    • Douglas Altman, Guillermo Carroli, Lelia Duley, Barbara Farrell, Jack Moodley, James Neilson, David Smith, and Magpie Trial Collaboration Group.
    • Lancet. 2002 Jun 1;359(9321):1877-90.

    BackgroundAnticonvulsants are used for pre-eclampsia in the belief they prevent eclamptic convulsions, and so improve outcome. Evidence supported magnesium sulphate as the drug to evaluate.MethodsEligible women (n=10141) had not given birth or were 24 h or less postpartum; blood pressure of 140/90 mm Hg or more, and proteinuria of 1+ (30 mg/dL) or more; and there was clinical uncertainty about magnesium sulphate. Women were randomised in 33 countries to either magnesium sulphate (n=5071) or placebo (n=5070). Primary outcomes were eclampsia and, for women randomised before delivery, death of the baby. Follow up was until discharge from hospital after delivery. Analyses were by intention to treat.FindingsFollow-up data were available for 10,110 (99.7%) women, 9992 (99%) of whom received the allocated treatment. 1201 of 4999 (24%) women given magnesium sulphate reported side-effects versus 228 of 4993 (5%) given placebo. Women allocated magnesium sulphate had a 58% lower risk of eclampsia (95% CI 40-71) than those allocated placebo (40, 0.8%, vs 96, 1.9%; 11 fewer women with eclampsia per 1000 women). Maternal mortality was also lower among women allocated magnesium sulphate (relative risk 0.55, 0.26-1.14). For women randomised before delivery, there was no clear difference in the risk of the baby dying (576, 12.7%, vs 558, 12.4%; relative risk 1.02, 99% CI 0.92-1.14). The only notable difference in maternal or neonatal morbidity was for placental abruption (relative risk 0.67, 99% CI 0.45-0.89).InterpretationMagnesium sulphate halves the risk of eclampsia, and probably reduces the risk of maternal death. There do not appear to be substantive harmful effects to mother or baby in the short term.

      Pubmed     Full text  

      Add institutional full text...

    This article appears in the collections: Landmark articles in Intensive Care Medicine, Landmark articles in Anesthesia, Landmark obstetric anesthesia papers, and The wonderful world of perioperative magnesium.

    Notes

    pearl
    1

    Magnesium sulphate halves the risk of eclampsia in pre-eclamptic pregnant women without significant adverse effect.

    Daniel Jolley  Daniel Jolley
     
    Do you have a pearl, summary or comment to save or share?
    250 characters remaining
    help        
    You can also include formatting and links in your notes
    • Simple formatting can be added to notes, such as _italic_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
795,009 articles already indexed!

We guarantee your privacy. Your email address will not be shared.